CD20 Expression in Hodgkin and Reed-Sternberg Cells of Classical Hodgkin’s Disease: Associations With Presenting Features and Clinical Outcome

Abstract

CD20 is expressed by HRS cells in 22% of patients with classical HD but is not associated with different FFS after treatment with equivalent regimens.

Synthesis, X-ray structures and cytotoxic activity of platinum(II), palladium(II) and copper(II) complexes with chelating ligands

“…Overexpressed BAX accelerates apoptotic death induced by cytokine deprivation in an IL-3-dependent cell line. Overexpressed BAX also counters the death-repressor activity of Bcl-2 [16]. The expression of the BAX gene is regulated by the tumor suppressor P53 and has been shown to be involved in P53-induced apoptosis.…”

Hodgkin Lymphoma

“…CD20 is a transmembrane protein involved in B cell growth and differentiation. Rassidakis et al reported that CD20 was expressed by HRS cells in 22% of patients with classical Hodgkin disease [4]. Eberle et al reviewed the histopathology of Hodgkin lymphoma and immunostaining available for diagnosis in clinical settings [5].…”

Does Rituximab Have a Place in Treating Classic Hodgkin Lymphoma?

“…In fact, several naked and conjugated monoclonal antibodies targeting surface proteins that are expressed on the malignant Hodgkin and Reed-Sternberg (HRS) cells are currently under intensive investigation, with promising early results (Table 1). Of particular interest is the CD20 antigen, because it is expressed not only on a fraction of HRS cells but also on the benign reactive B cells in the microenvironment [4]. CD20 can be targeted by rituximab, a commercially available chimeric antibody that is approved by the US Food and Drug Administration for the treatment of CD20-positive B-cell non-Hodgkin lymphoma.…”